Searchable abstracts of presentations at key conferences in endocrinology

ea0029s9.3 | The risk and benefits of tight glycaemic control | ICEECE2012

Time course of the glucose legacy effect

Holman R.

During the 10-year UK Prospective Diabetes Study (UKPDS) post-trial monitoring period, sustained reductions were seen in the risks of diabetic complications, despite the previously randomised conventional and intensive treatment groups becoming identical with respect to median HbA1c values and glucose-lowering therapies. This continuing benefit of an earlier intervention in people with type 2 diabetes has been termed the ‘legacy effect’. A similar phenomenon seen in ...

ea0003s14 | Vascular Risk in Diabetes - Genetic and Environmental Interactions | BES2002

Diabetes and vascular risk

Holman R

The number of people world wide with diabetes is predicted to double to 221 million by the year 2010. Diabetes remains the leading cause of blindness, end stage renal disease and lower extremity amputations in the United States but the greatest impact of the disease is the two to four times greater risk of coronary heart disease (CHD) and stroke. Of the 5102 patients, aged 25 to 65 years with newly diagnosed type 2 diabetes recruited into the UK Prospective Diabetes Study (UKP...

ea0004ds8 | Treatment of insulin resistance or post-prandial hyperglycaemia - contrasting evidence | SFE2002

The Role of Metformin

Holman R , Stratton I

The UKPDS trial confirmed that improving glycaemic control (median 0.9 % HbA1c difference over median 10 years), with sulphonylurea or insulin therapy, could reduce significantly the risk of microvascular complications (25%, p=0.0099) and was associated with a 16% trend (p=0.052) to a reduced risk of coronary heart disease (CHD). In overweight UKPDS patients allocated metformin as first line therapy the 0.6% median HbA1c difference obtained was associated...